| scholarly article | Q13442814 |
| P356 | DOI | 10.1523/JNEUROSCI.1830-07.2007 |
| P8608 | Fatcat ID | release_iqewb3e54rfjhd4wwkbbxk5n5i |
| P3181 | OpenCitations bibliographic resource ID | 1196884 |
| P932 | PMC publication ID | 6672210 |
| P698 | PubMed publication ID | 17715336 |
| P2093 | author name string | Peter J Detloff | |
| Roger L Albin | |||
| Sara J Tallaksen-Greene | |||
| Mary Y Heng | |||
| P2860 | cites work | A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. | Q27860836 |
| Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice | Q28505664 | ||
| Neurological abnormalities in a knock-in mouse model of Huntington's disease | Q28508179 | ||
| Cellular localization and development of neuronal intranuclear inclusions in striatal and cortical neurons in R6/2 transgenic mice | Q28510296 | ||
| Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats | Q28587110 | ||
| Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes | Q28588235 | ||
| A Huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice | Q28594336 | ||
| Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice | Q29615357 | ||
| Huntington's disease: a synaptopathy? | Q33193898 | ||
| Differential loss of striatal projection neurons in Huntington disease | Q33637273 | ||
| Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. | Q33857802 | ||
| Fourteen and counting: unraveling trinucleotide repeat diseases | Q33892634 | ||
| Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy | Q34023072 | ||
| Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course | Q34181024 | ||
| Beyond the Qs in the polyglutamine diseases | Q34228238 | ||
| Regional changes in forebrain activation during the early and late phase of formalin nociception: analysis using cerebral blood flow in the rat | Q35724229 | ||
| Cardiac dysfunction in the R6/2 mouse model of Huntington's disease | Q35745626 | ||
| The genetics of neurodegenerative diseases | Q36521941 | ||
| Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene | Q37432151 | ||
| Onset and rate of striatal atrophy in preclinical Huntington disease | Q40496996 | ||
| Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis | Q40585913 | ||
| Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. | Q40661429 | ||
| Homozygosity for Machado-Joseph disease gene enhances phenotypic severity | Q41917261 | ||
| Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage | Q42512972 | ||
| Hprt(CAG)146 mice: age of onset of behavioral abnormalities, time course of neuronal intranuclear inclusion accumulation, neurotransmitter marker alterations, mitochondrial function markers, and susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydro | Q44569570 | ||
| Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation | Q45173078 | ||
| Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease | Q45289366 | ||
| Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease | Q45292176 | ||
| PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease | Q45294163 | ||
| Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes | Q45295568 | ||
| Alterations in dopamine and benzodiazepine receptor binding precede overt neuronal pathology in mice modelling early Huntington disease pathogenesis | Q45296282 | ||
| A combination drug therapy improves cognition and reverses gene expression changes in a mouse model of Huntington's disease. | Q45296305 | ||
| Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. | Q45296558 | ||
| Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin | Q45297223 | ||
| Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice | Q45298284 | ||
| Early behavioral deficits in R6/2 mice suitable for use in preclinical drug testing | Q45298349 | ||
| Regional cortical thinning in preclinical Huntington disease and its relationship to cognition | Q45298420 | ||
| Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease. | Q45298570 | ||
| A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. | Q45298582 | ||
| Decreased striatal monoaminergic terminals in Huntington disease | Q45300337 | ||
| Neuronal intranuclear inclusions and neuropil aggregates in HdhCAG(150) knockin mice | Q45303809 | ||
| Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain | Q45304077 | ||
| Regional and progressive thinning of the cortical ribbon in Huntington's disease | Q45305508 | ||
| Huntington disease. | Q48465200 | ||
| Homozygous inheritance of the Machado-Joseph disease gene | Q57419142 | ||
| P433 | issue | 34 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Huntington's disease | Q190564 |
| Huntingtin | Q14882525 | ||
| murine model | Q122890741 | ||
| P304 | page(s) | 8989-8998 | |
| P577 | publication date | 2007-08-01 | |
| P1433 | published in | Journal of Neuroscience | Q1709864 |
| P1476 | title | Longitudinal evaluation of the Hdh(CAG)150 knock-in murine model of Huntington's disease | |
| P478 | volume | 27 |
| Q39732144 | A Drosophila model of Huntington disease-like 2 exhibits nuclear toxicity and distinct pathogenic mechanisms from Huntington disease |
| Q37089398 | A Longitudinal Motor Characterisation of the HdhQ111 Mouse Model of Huntington's Disease |
| Q28391627 | A broad phenotypic screen identifies novel phenotypes driven by a single mutant allele in Huntington's disease CAG knock-in mice |
| Q35951187 | A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease |
| Q35063135 | A knockin mouse model of spinocerebellar ataxia type 3 exhibits prominent aggregate pathology and aberrant splicing of the disease gene transcript. |
| Q38974551 | A link between chromatin condensation mechanisms and Huntington's disease: connecting the dots. |
| Q91818244 | Abnormalities in the Motor Unit of a Fast-Twitch Lower Limb Skeletal Muscle in Huntington's Disease |
| Q37323312 | Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's disease. |
| Q36984277 | Age-Dependent Resistance to Excitotoxicity in Htt CAG140 Mice and the Effect of Strain Background. |
| Q53070588 | Age-associated bimodal transcriptional drift reduces intergenic disparities in transcription. |
| Q24657764 | Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease |
| Q36722685 | Allelic series of Huntington's disease knock-in mice reveals expression discorrelates |
| Q47138180 | Altered Aconitase 2 Activity in Huntington's Disease Peripheral Blood Cells and Mouse Model Striatum |
| Q35560350 | Altered excitatory and inhibitory inputs to striatal medium-sized spiny neurons and cortical pyramidal neurons in the Q175 mouse model of Huntington's disease |
| Q30496179 | Automated quantitative gait analysis in animal models of movement disorders |
| Q36608360 | Bone marrow transplantation confers modest benefits in mouse models of Huntington's disease |
| Q50421506 | Cell-specific deletion of PGC-1α from medium spiny neurons causes transcriptional alterations and age-related motor impairment. |
| Q45292629 | Changes in Dopamine Signalling Do Not Underlie Aberrant Hippocampal Plasticity in a Mouse Model of Huntington's Disease. |
| Q28546047 | Characterization of HTT inclusion size, location, and timing in the zQ175 mouse model of Huntington's disease: an in vivo high-content imaging study |
| Q38139868 | Choosing an animal model for the study of Huntington's disease |
| Q47882715 | Comparison of spinocerebellar ataxia type 3 mouse models identifies early gain-of-function, cell-autonomous transcriptional changes in oligodendrocytes. |
| Q34531481 | Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175. |
| Q33630679 | Conditional Niemann-Pick C mice demonstrate cell autonomous Purkinje cell neurodegeneration. |
| Q36252810 | Correlations of Behavioral Deficits with Brain Pathology Assessed through Longitudinal MRI and Histopathology in the HdhQ150/Q150 Mouse Model of Huntington's Disease |
| Q27320487 | Cpd-1 null mice display a subtle neurological phenotype |
| Q90457386 | DNA damage and synaptic and behavioural disorders in glucose-6-phosphate dehydrogenase-deficient mice |
| Q34112214 | Early autophagic response in a novel knock-in model of Huntington disease |
| Q35205602 | Early changes in cerebellar physiology accompany motor dysfunction in the polyglutamine disease spinocerebellar ataxia type 3 |
| Q35253106 | Early white matter abnormalities, progressive brain pathology and motor deficits in a novel knock-in mouse model of Huntington's disease |
| Q34095823 | Examination of Huntington's disease in a Chinese family |
| Q41884630 | Expanded CAG repeats in the murine Huntington's disease gene increases neuronal differentiation of embryonic and neural stem cells |
| Q30437914 | Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice |
| Q33755845 | Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression |
| Q37165188 | Genetic manipulations of mutant huntingtin in mice: new insights into Huntington's disease pathogenesis |
| Q37731940 | Genetic mouse models of Huntington's disease: focus on electrophysiological mechanisms |
| Q35056067 | HD CAG-correlated gene expression changes support a simple dominant gain of function |
| Q37840353 | Huntington's disease: can mice lead the way to treatment? |
| Q45293042 | In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease. |
| Q35547881 | Intracellular FGF14 (iFGF14) Is Required for Spontaneous and Evoked Firing in Cerebellar Purkinje Neurons and for Motor Coordination and Balance |
| Q30540206 | Lamin B1 mediates cell-autonomous neuropathology in a leukodystrophy mouse model |
| Q44250471 | Longitudinal analysis of the electroencephalogram and sleep phenotype in the R6/2 mouse model of Huntington's disease. |
| Q36119202 | Longitudinal in vivo MRI in a Huntington's disease mouse model: Global atrophy in the absence of white matter microstructural damage |
| Q58764354 | Metformin reverses early cortical network dysfunction and behavior changes in Huntington's disease |
| Q33809556 | Microglial Activation in the Pathogenesis of Huntington's Disease |
| Q33529492 | Monkey hybrid stem cells develop cellular features of Huntington's disease |
| Q42155772 | Mouse models of Huntington disease: variations on a theme. |
| Q30481208 | Mouse models of Huntington's disease and methodological considerations for therapeutic trials |
| Q47998495 | Mouse models of neurodegenerative disease: preclinical imaging and neurovascular component. |
| Q26853025 | Mouse models of polyglutamine diseases: review and data table. Part I |
| Q27305680 | Mutant huntingtin gene-dose impacts on aggregate deposition, DARPP32 expression and neuroinflammation in HdhQ150 mice |
| Q90439419 | Overview of Huntington's Disease Models: Neuropathological, Molecular, and Behavioral Differences |
| Q37930190 | Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function. |
| Q91695065 | Phenotype onset in Huntington's disease knock-in mice is correlated with the incomplete splicing of the mutant huntingtin gene |
| Q34463222 | Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity. |
| Q34627066 | Preferential accumulation of N-terminal mutant huntingtin in the nuclei of striatal neurons is regulated by phosphorylation |
| Q99638675 | Progression of basal ganglia pathology in heterozygous Q175 knock-in Huntington's disease mice |
| Q39124557 | Proteins Containing Expanded Polyglutamine Tracts and Neurodegenerative Disease |
| Q36553261 | Purkinje cell dysfunction and loss in a knock-in mouse model of Huntington disease |
| Q47634293 | Sex-dependent behavioral impairments in the HdhQ350/+ mouse line |
| Q55284103 | Striatal Mutant Huntingtin Protein Levels Decline with Age in Homozygous Huntington's Disease Knock-In Mouse Models. |
| Q30581974 | Studies on the Q175 Knock-in Model of Huntington's Disease Using Functional Imaging in Awake Mice: Evidence of Olfactory Dysfunction |
| Q55427881 | The adjustment of γ-aminobutyric acidA tonic subunits in Huntington's disease: from transcription to translation to synaptic levels into the neostriatum. |
| Q41967848 | The challenge in translating basic research discoveries to treatment of Huntington disease |
| Q37663855 | The de-ubiquitinating enzyme ataxin-3 does not modulate disease progression in a knock-in mouse model of Huntington disease |
| Q45304764 | The ubiquitin conjugating enzyme Ube2W regulates solubility of the Huntington's disease protein, huntingtin. |
| Q26849677 | Transgenic animal models for study of the pathogenesis of Huntington's disease and therapy |
| Q92775462 | Uses for humanised mouse models in precision medicine for neurodegenerative disease |
Search more.